key: cord-0992633-si23grvx
authors: Han, Jin H.; Womack, Kelsey N.; Tenforde, Mark W.; Files, D. Clark; Gibbs, Kevin W.; Shapiro, Nathan I.; Prekker, Matthew E.; Erickson, Heidi L.; Steingrub, Jay S.; Qadir, Nida; Khan, Akram; Hough, Catherine L.; Johnson, Nicholas J.; Ely, E. Wesley; Rice, Todd W.; Casey, Jonathan D.; Lindsell, Christopher J.; Gong, Michelle N.; Srinivasan, Vasisht; Lewis, Nathaniel M.; Patel, Manish M.; Self, Wesley H.
title: Associations between persistent symptoms after mild COVID‐19 and long‐term health status, quality of life, and psychological distress
date: 2022-03-28
journal: Influenza Other Respir Viruses
DOI: 10.1111/irv.12980
sha: ffd44a46657ceacc34da646ffd5b9d0a175c757b
doc_id: 992633
cord_uid: si23grvx

BACKGROUND: We sought to assess whether persistent COVID‐19 symptoms beyond 6 months (Long‐COVID) among patients with mild COVID‐19 is associated with poorer health status, quality of life, and psychological distress. METHODS: This was a multicenter prospective cohort study that included adult outpatients with acute COVID‐19 from eight sites during 2‐week sampling periods from April 1 and July 28, 2020. Participants were contacted 6–11 months after their first positive SARS‐CoV‐2 to complete a survey, which collected information on the severity of eight COVID‐19 symptoms using a 4‐point scale ranging from 0 (not present) to 3 (severe) at 1 month before COVID‐19 (pre‐illness) and at follow‐up; the difference for each was calculated as an attributable persistent symptom severity score. A total attributable persistent COVID‐19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long‐term follow‐up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ‐5D‐5L), and psychological distress (Patient Health Questionnaire‐4). The association between the total attributable persistent COVID‐19 burden score and each outcome was analyzed using multivariable proportional odds regression. RESULTS: Of the 2092 outpatients with COVID‐19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID‐19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57–0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59–0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28–1.54) after adjusting for age, race, ethnicity, education, and income. CONCLUSIONS: In participants with mild acute COVID‐19, the burden of persistent symptoms was significantly associated with poorer long‐term health status, poorer quality of life, and psychological distress.

A total attributable persistent COVID-19 symptom burden score was calculated by summing the attributable persistent severity scores for all eight symptoms. Outcomes measured at long-term follow-up comprised overall health status (EuroQol visual analogue scale), quality of life (EQ-5D-5L), and psychological distress (Patient Health Questionnaire-4). The association between the total attributable persistent COVID-19 burden score and each outcome was analyzed using multivariable proportional odds regression.

Results: Of the 2092 outpatients with COVID-19, 436 (21%) responded to the survey. The median (IQR) attributable persistent COVID-19 symptom burden score was 2 (0, 4); higher scores were associated with lower overall health status (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life (aOR: 0.65; 95%CI: 0.59-0.72), and higher psychological distress (aOR: 1.40; 95%CI, 1.28-1.54) after adjusting for age, race, ethnicity, education, and income.

Conclusions: In participants with mild acute COVID-19, the burden of persistent symptoms was significantly associated with poorer long-term health status, poorer quality of life, and psychological distress. or Long-COVID, characterized by symptoms that persist for months after the initial infection. [3] [4] [5] [6] [7] Most prior studies evaluating PASC were conducted among patients who were hospitalized with moderate to severe COVID-19, which may not be generalizable to patients with mild COVID-19 who were never hospitalized. Furthermore, most prior studies did not account for the presence of symptoms before a diagnosis of COVID-19 illness, making it difficult to understand if persistent post-illness symptoms represented a return to a pre-illness baseline or new morbidity attributable to COVID-19.

A growing body of literature also suggests that many people report poor quality of life and high psychological distress months after an initial diagnosis of COVID-19. [4] [5] [6] 8 The mechanisms and risk factors for long-term morbidity following COVID-19 illness remain poorly understood. To address these knowledge gaps, we sought to characterize COVID-19 symptom trajectories before, during, and 6-11 months after acute mild COVID-19 illness and evaluate long-term self-reported health status, quality of life, and psychological distress.

We hypothesized that: (1) some outpatients with mild COVID-19 would exhibit substantial, persistent symptoms at 6-11 months after initial diagnosis; and (2) the burden of persistent symptoms would be associated with lower health status and quality of life, and higher psychological distress.

A multicenter prospective cohort study conducted by the Influenza and Other Viruses in the Acutely Ill (IVY) Network, which is a collaboration among 21 academic medical centers in the United States (US) and the Centers for Disease Control and Prevention (CDC) and coordinated at Vanderbilt University Medical Center. 9,10 As previously described, [11] [12] [13] sites obtained lists of outpatient adults who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) testing of a nasal swab during discrete two-week periods between April 1, 2020, and July 28, 2020.

Eight IVY centers from seven US states participated in this analysis. This analysis included participants who indicated that they had symptoms of COVID-19 at the time of the positive SARS- 

Data were collected through two sources: the local sites' electronic medical records and by Twilio (Cloud communications platform, San Francisco, CA). The electronic medical record was used as a source for SARS-CoV-2 test dates and results. Twilio is a software application that sent survey links to participants via SMS text message on February 4, 2021, with serial text message reminders sent to those who had not responded over the subsequent month. The survey assessed symptoms at 6-11 months after the initial positive SARS-CoV-2 test well as self-assessed health status, quality of life, and psychological distress. For this project, Twilio was integrated into a REDCap data collection tool, which was used to store all data.

The survey, available in the supporting information, was administered in two parts. Part 1 of the survey asked participants if they were still experiencing physical or mental problems related to COVID-19. Those who had persistent symptoms at long-term follow-up were asked to report the most severe symptom still present. Those who had no persistent symptoms at long-term followup were asked how long it took to recover from their COVID-19 symptoms.

All participants who completed Part 1 were also invited to complete Part 2 of the survey, which collected demographic data and asked participants to classify the severity of eight symptoms associated with PASC in previous studies (fatigue, difficulty sleeping, difficulty concentrating, difficulty completing usual daily tasks, shortness of breath, loss of taste, loss of smell, and hair loss) at three time points: 1 month before the onset of COVID-19 symptoms (pre-illness baseline), at the worst point during acute COVID-19 (peak symptoms), and currently at the time of survey completion (long-term follow-up, 6-11 months after the initial positive SARS-CoV-2 test). The severity of each symptom was classified using a 4-level ordinal scale that ranged from 0 (not present) to 3 (severe) (Table S1 ).

An attributable persistent COVID-19 symptom severity score was calculated for each individual symptom as: long-term follow-up score minus pre-illness baseline score. For example, if a patient reported a fatigue score of 3 at long-term follow-up and a baseline fatigue score of 1, the persistent COVID-19 fatigue score would be 2. An attributable persistent score ≥1 indicated symptoms were more severe 6-11 months after acute COVID-19 than before COVID-19. The term "attributable" was used to indicate that the score accounted for preillness baseline symptoms. The term "persistent" was used to indicate the symptoms were present beyond 6 months from the onset of COVID-19. A total attributable persistent COVID-19 symptom burden score was calculated by summing the eight symptom-specific scores.

This resulted in a total score with a range of À24 to 24, with positive scores indicating symptoms beyond a pre-COVID baseline that were still present at follow-up.

Part 2 of the Twilio survey also asked participants to report information on three outcomes: overall health status, quality of life, and psychological distress. For overall health status, participants rated their self-assessed health using the EuroQol Visual Analog Scale (EQ-VAS) for 1 month before the COVID-19 illness (pre-illness baseline) and at long-term follow-up. The EQ-VAS ranges from 0 (worst health imaginable) to 100 (best health imaginable). 14 A change in EQ-VAS by ≥8 points between the pre-illness baseline and long-term follow-up was considered clinically important. 15, 16 Participants reported quality of life at long-term follow-up using the EQ-5D-5L, a 5-question instrument that captures impairments in mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression. 17 EQ-5D-5L scores were summarized using the index value validated for the US population. 18 An index value of 1.0 indicated perfect health, a value of 0.0 indicated death, and a value <0.0 indicated quality of life the participant rated as worse than death. 18 Participants reported information on psychological distress at long-term follow-up using the Patient Health Questionnaire-4 (PHQ-4). 19 This 4-item survey was used to grade the severity of depression and anxiety symptoms, with scores ranging from 0 (no symptoms) to 12 (severe symptoms). A score of ≤2 was interpreted as no psychological distress.

COVID-19 symptom trajectory was summarized by reporting median and interquartile range (IQR) values and displaying box-and-whisker plots for symptom severity scores at three time points: pre-illness baseline, peak acute COVID-19, and long-term follow-up (6-11 months after the initial positive SARS-CoV-2 test). The association between the total attributable persistent COVID-19 symptom burden score and each outcome (overall health status, quality of life, and psychological distress) was evaluated using multivariable proportional odds regression models. Proportional odds regression was used due to the non-parametric distribution of the outcome variables. In each model, the total attributable persistent COVID-19 symptom burden score was the primary independent variable, the outcome score was the dependent variable, and covariables included age, race, ethnicity, education level, income level, and pre-COVID overall health status (baseline EQ-VAS score). Details of the model covariables are described in Table S2 . The proportional odds regression models produced adjusted odds ratios (aOR) with 95% confidence intervals (95% CI) summarizing the association between the total attributable persistent COVID-19 symptom burden score and each of the three outcomes. An aOR < 1 indicated an association between higher persistent symptom burden and lower overall health status and quality of life (worse outcomes). An aOR > 1 indicated an association between higher persistent symptom burden and higher psychological distress (worse outcome). Analyses were conducted with SAS Version 9.4 (SAS Institute, Cary, NC). Table S3 ). Of 221 participants who did not have persistent symptoms (i.e., were recovered) at long-term follow-up, 122 (55%) had recovered in <1 month, 74 (33%) recovered in 1-3 months, 20 (9%) had recovered in 3-6 months, and 5 (2%) had recovered after 6 months.

Part 2 of the survey with outcome data was completed by 213 participants; 105/176 (60%) participants who reported persistent symptoms on the Part 1 survey went on to complete Part 2, and 108/221 (49%) who did not report persistent symptoms in Part 1 also completed Part 2. The median (IQR) age of these participants was 45 (33, 57) years, 141 (66%) were women, 43 (20%) were Hispanic, 32 (15%) were non-Hispanic Black, 40 (19%) had a high school degree or below, and 56 (26%) had a household income less than $50 000 ( Table 1) . The median (IQR) pre-Illness EQ-VAS overall health status score was 86 (75, 93).

COVID-19 symptom trajectories from 1 month before COVID-19 symptom onset (pre-illness), during peak acute COVID-19, and to long-term follow-up (6 to 11 months after the initial positive SARS-CoV-2 test) are displayed in Figure 2 . Several patterns of symptom trajectories were observed. Loss of taste and smell were very rare before COVID-19, tended to become severe for many participants during acute COVID-19, and then completely resolved for nearly all participants by long-term follow-up. Shortness of breath and difficulty with usual tasks were rare before COVID-19, became severe for many participants during peak COVID-19, and persisted for a minority at long-term follow-up. Fatigue and difficulty concentrating were present at low levels for many participants prior to COVID-19, peaked at high levels during acute illness, and then tended to decline somewhat by long-term follow-up, but not all the way down to pre-illness levels.

Among 213 respondents to Part 2 of the survey, 154 (72%) had at least one symptom that was more severe at long-term follow-up than pre-illness baseline (attributable persistent symptom score ≥1).

The percentage of patients with an attributable persistent symptom score ≥1 ranged across symptoms from 17% for hair loss to 41% for fatigue ( Table 2) . Of note, an attributable persistent symptom score ≥1 was reported by 33% for difficulty concentrating and 32% for shortness of breath. Furthermore, 65 (31%) respondents had at least one symptom with an attributable persistent symptom score ≥2. The percentage of patients with an attributable persistent symptom score ≥2 ranged from 4% for sleep to 11% for fatigue. At long-term follow-up, the median (IQR) score for EQ-VAS was 78 (69, 89), for EQ-5D-5L was 0.90 (0.79, 1.00), and for PHQ-4 was 2 (0, 4) ( Table 3 ). The median (IQR) decline in EQ-VAS score between pre-illness baseline and long-term follow-up was 5 (0, 15) points, with 86 (40%) participants having a decline of ≥8 points, which was considered clinically important.

The total attributable persistent COVID-19 burden score was significantly associated with worse outcomes at long-term follow-up, including lower overall health status measured by EQ-VAS (aOR 0.63; 95% CI: 0.57-0.69), lower quality of life measured by the EQ-5D-5L F I G U R E 2 Legend on next page.

attention and working memory are likely involved. 24 We observed that 32% of our outpatient cohort still had not returned to their preillness concentration status 6-11 months after acute illness. Other outpatient COVID-19 cohorts have reported prevalences of persistent "brain fog" ranging from 2% to 81%. 3 [25] [26] [27] One novel aspect of our study was the implementation of automated survey delivery using Twilio; survey links were sent to subjects' cellular phones using SMS text messaging and automatically sent reminders over a one-month period. We achieved a 21% overall response rate without providing advanced notice to the subject that an online survey would be sent and without providing financial reimbursement to responders. Obtaining long-term follow-up is often labor intensive and costly, especially for multi-center studies. Considerable effort is often expended in trying to contact patients for follow-up using traditional techniques, such as telephone banks. Using automated survey delivery tools could increase the feasibility and decrease the cost of obtaining long-term follow-up while also allowing participants to complete surveys at their own convenience. A limitation of this approach is the low response rate compared with traditional methods. Response rates could be improved by providing subject reimbursement, notifying subjects to expect an SMS text message with an online survey, or following up patients who do not respond to text-based surveys with telephone calls. 28 Our study had some additional limitations. First, the study population was a convenience sample of people who had COVID-19 as an outpatient in the United States during the spring and summer of 2020 and completed a cellular phone-based survey. The study was subject F I G U R E 2 Symptom trajectories from 1 month before COVID-19 (pre-illness baseline), during peak acute COVID-19 (worst during illness), and at long-term follow-up (6-11 months after the positive SARS-CoV-2 test) for 8 COVID-19 symptoms. Patients rated their symptoms using a 4-level Likert scale ranging from 0 (no symptoms) to 3 (severe symptoms). At each time point, a summary of symptom severity among all participants is plotted with a box plot, with the median score represented by the horizontal line, the interquartile range (25th percentile to 75th percentile) represented by the box, the full range represented by the outer brackets, and the mean represented by the star. A dashed line connects the median from each time point to highlight changes in the central tendency over time Participants were asked to rate the severity of eight symptoms at three time points: before COVID-19 (pre-illness baseline), during the peak of their COVID-19 illness (peak symptoms), and at 6-11 months after the positive SARS-CoV-2 test (long-term follow-up). The severity of symptoms was rated using a 4-level Likert scale ranging from 0 (no symptoms) to 3 (severe symptoms). The attributable persistent COVID-19 score was calculated as the longterm follow-up score minus the pre-illness baseline score. This The association between the total attributable persistent COVID-19 burden score (a measure of burden of persistent COVID-19 symptoms) and each outcome was analyzed using multivariable proportional odds regression. This table includes 213 participants who responded to Part 2 of the long-term follow-up survey. b Overall health status was measured using the EuroQol visual analogue scale (EQ-VAS), which asked participants to rate their health from 0 (worst health) to 100 (best health). Quality of life was measured with the EQ-5D-5L, which measures the participant's mobility, self-care, activities, pain, and anxiety, and is summarized with a utility score ranging from <0 (worse than death) to 1.0 (perfect health). Psychological distress was measured with the Patient Health Questionnaire-4 (PHQ-4), a 4-item questionnaire that grades the severity of depression and anxiety and ranges from 0 (no symptoms) to 12 (severe psychological distress). Wesley H. Self: Conceptualization; funding acquisition; investigation; methodology; project administration; supervision.

The peer review history for this article is available at https://publons. com/publon/10.1111/irv.12980.

A de-identified dataset for this study may be requested from CDC (www.cdc.gov/info).

Jin H. Han https://orcid.org/0000-0003-0384-210X

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020

Post-acute COVID-19 syndrome

Sequelae in Adults at 6 Months After COVID-19 Infection

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Persistent Symptoms in Patients After Acute COVID-19

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

More than 50 long-term effects of COVID-19: a systematic review and metaanalysis

Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Influenza and Other Viruses in the Acutely Ill (IVY) Network Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Telework before illness onset among symptomatic adults aged >/=18 years with and without COVID-19 in 11 outpatient health care facilities-United States

Community and close contact exposures associated with COVID-19 among symptomatic adults >/=18 years in 11 outpatient health care facilities-United States

Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States

EQ-5D: a measure of health status from the EuroQol Group

Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation

Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD

Valuation of EuroQOL (EQ-5D) health states in an adult US sample

United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value Health

An ultra-brief screening scale for anxiety and depression: the PHQ-4

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers

CoviCare Study T. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting

Feel Like I Have Dementia': brain fog plagues covid survivors

Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients

A clinic blueprint for post-coronavirus disease 2019 recovery: learning from the past, looking to the future

An integrated multidisciplinary model of COVID-19 recovery care

Evaluating and caring for patients with post-COVID conditions: interim guidance

Improving survey response rates in online panels: effects of low-cost incentives and cost-free text appeal interventions

Mobile fact sheet

00084-5 SUPPORTING INFORMATION Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article